Lecap Asset Management Ltd. Acquires Shares of 61,831 Edwards Lifesciences Co. (NYSE:EW)

Lecap Asset Management Ltd. bought a new position in shares of Edwards Lifesciences Co. (NYSE:EW) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 61,831 shares of the medical research company’s stock, valued at approximately $4,080,000. Edwards Lifesciences makes up approximately 0.9% of Lecap Asset Management Ltd.’s portfolio, making the stock its 12th biggest position.

A number of other institutional investors have also recently modified their holdings of EW. Allspring Global Investments Holdings LLC increased its holdings in Edwards Lifesciences by 4.4% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 330,711 shares of the medical research company’s stock worth $31,603,000 after acquiring an additional 14,087 shares in the last quarter. Empowered Funds LLC increased its stake in shares of Edwards Lifesciences by 151.2% during the first quarter. Empowered Funds LLC now owns 20,123 shares of the medical research company’s stock worth $1,923,000 after purchasing an additional 12,112 shares in the last quarter. Cetera Advisors LLC raised its position in shares of Edwards Lifesciences by 175.1% during the 1st quarter. Cetera Advisors LLC now owns 38,090 shares of the medical research company’s stock worth $3,640,000 after purchasing an additional 24,242 shares during the last quarter. Financial Sense Advisors Inc. purchased a new position in Edwards Lifesciences in the 1st quarter valued at about $975,000. Finally, BDF Gestion acquired a new stake in Edwards Lifesciences in the 2nd quarter worth about $5,148,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,101,530.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at $3,101,530.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Daveen Chopra sold 1,250 shares of the stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the sale, the vice president now owns 29,333 shares in the company, valued at approximately $2,051,843.35. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 16,250 shares of company stock worth $1,099,238 in the last three months. 1.29% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Wolfe Research upgraded Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research report on Monday, July 29th. Royal Bank of Canada lowered their target price on shares of Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Barclays reduced their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Stifel Nicolaus lowered their price target on shares of Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating on the stock in a research report on Thursday, July 25th. Finally, UBS Group cut their price objective on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a report on Tuesday, September 10th. Fifteen research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $75.81.

Edwards Lifesciences Stock Down 1.2 %

Edwards Lifesciences stock opened at $69.24 on Wednesday. The company has a market capitalization of $41.72 billion, a PE ratio of 29.84, a price-to-earnings-growth ratio of 2.83 and a beta of 1.13. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The firm has a 50 day moving average price of $67.96 and a 200 day moving average price of $78.76.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The business had revenue of $1.63 billion during the quarter, compared to analysts’ expectations of $1.65 billion. During the same period in the previous year, the firm posted $0.66 earnings per share. The company’s revenue was up 6.7% on a year-over-year basis. Research analysts expect that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.